ARCH Venture Partners raises $3 billion to invest in biotech

Chicago, USA-based ARCH Venture Partners has announced the closing of a $2.975 billion fund to invest in the creation, development and funding of early-stage biotech companies.

The ARCH Venture Fund XII follows the January 2021 announcement of the previous incarnation, which was worth almost $2 billion.

"Our approach has always been to pair great science with remarkable, proven teams to build disruptive companies"ARCH co-founder and managing director, Robert Nelsen, said: “All the fundamental innovations in biotechnology are accelerating, with huge promise for new preventive, disease-modifying, and even curative treatments. Science doesn’t care what markets are doing, and science moves forward. With over 35 years of venture experience, ARCH has been creating and consolidating companies for the long term.”